ORPHA:480851
Hereditary thrombocytopenia with early-onset myelofibrosis
Publications
3,369
Trials
0
Interventional, condition-specific
Researchers
1,488
Distinct authors in sample
Gene link
SRC
Strong
Readiness
3/6
Stages with a signal
Clinical definition (Orphanet)
A rare syndromic constitutional thrombocytopenia characterized by thrombocytopenia with increased bleeding tendency (leading to epistaxis, menorrhagia, and petechiae), in combination with myelofibrosis and . Platelets may be abnormally large or small and partly hypo- or agranular, plasma thrombopoietin is elevated, and the number of megakaryocytes in the bone marrow increased. Additional non-hematologic manifestations have been described in some patients, including mild bone abnormalities and facial dysmorphism with large forehead, hypertelorism, deep-set eyes, and wide nostrils.
How rare: <1 / 1 000 000 — fewer than one in a million. In a city the size of Kolkata, that might mean on the order of fifteen people.
Cross-references
Joined from Mondo / Orphanet. MeSH labels may enter searches; UMLS / OMIM / NCIT are stored for reference.
- MONDO:0014837
- OMIM:616937
- UMLS:C4310789
Additional Mondo synonyms (3)
hereditary thrombocytopenia with early-onset myelofibrosis · thrombocytopenia 6 · thrombocytopenia type 6
Research stages
Trial readiness signals
Where this condition sits on an open-data research pipeline — not how close a treatment is, and not medical advice. Empty stages often mean “not in these databases under this Mondo ID,” not “impossible.”
3/6 stages with a signal
No matched interventional trial; the gene is known and literature exists — preclinical or natural-history work may still be the practical next step.
- Gene identifiedPresent
Strong — SRC
- LiteraturePresent
3,369 matched papers (1,570 in last 10 years) Source
- Phenotype characterisedPresent
9 HPO annotations (e.g. Deeply set eye; Hypotelorism; Osteoporosis) Source
- Animal modelNot found
No Alliance genotype “model of” associations via Monarch for these Mondo IDs
- Orphan designationNot found
No FDA or EMA orphan-drug designation matched this disease via UMLS or preferred name Source
- Interventional trialNot found
No matched interventional trial under our ClinicalTrials.gov rules
Biology
Genes and phenotypes
Gene–disease validity from GenCC, plus phenotypes and animal models joined from Monarch Initiative via Mondo ID — not a clinical diagnosis aid.
Do we know what causes it?
Yes — we know a specific gene responsible (SRC).
GenCC classification: Strong.
Phenotypes (Monarch / HPO)
9
Associated phenotypes · MONDO:0014837
- Deeply set eye
- Hypotelorism
- Osteoporosis
- Abnormal bleeding
- Large forehead
Showing 5 of 9 — open Monarch for the full list.
Animal models (Monarch / Alliance)
None returned for this Mondo ID. Empty here is not proof that no model organism work exists under another name or gene.
Monarch fetch 2026-07-29
Therapies
Designations, candidates, and chemicals
FDA OOPD and EMA orphan designations, Open Targets clinical candidates, and CTD chemical associations via MyDisease.info. These never change the interventional-trial headline.
Orphan designation (FDA · EMA)
No designation matched this disease via UMLS or preferred name on the FDA OOPD mirror or EMA orphan register. Absence here is not proof that none exists under another wording.
Open Targets candidates
No drugs or clinical candidates returned for this Mondo ID on Open Targets.
CTD chemicals (MyDisease.info)
No CTD chemical associations returned for this Mondo ID.
Literature
Is anyone studying this?
3,369
3,369 papers have been published on this condition. That is a real research literature — still far smaller than common diseases (breast cancer: over 700,000 papers). Median papers in the last 10 years for a rare disease in this dataset (publications denominator n=3967) is 59.
3,369 papers since the earliest indexed year in this search — median last-10-year count for a rare disease in this dataset is 59 (publications denominator n=3967).
1,570 in the last 10 years · low confidence
Phrase hits: 1,647 · MeSH hits: 0
Who's working on it?
1,488
Distinct author names in 200 sampled papers — named people below.
Who's working on it?
No interventional trial matched this name; these authors publish on it in the sampled literature — a practical starting point for contact.
- 01Liu J4 papers · 2026
Department of Clinical Laboratory, Shenzhen Children's Hospital, Shenzhen 518038, China.
Papers in Europe PMC - 02Wang X4 papers · 2026
Department of Oncology and Vascular Interventional Therapy, Clinical Oncology School of Fujian Medical University, Fujian Cancer Hospital, Fuzhou, 350014, China.
Papers in Europe PMC - 03Yang X4 papers · 2026
Department of Liver Surgery, State Key Laboratory of Complex Severe and Rare Diseases, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, China. Electronic address: yangxiaobo67@pumch.cn.
Papers in Europe PMC - 04Zhang L4 papers · 2026
Department of Respiratory and Critical Care Medicine, First Affiliated Hospital of Wannan Medical College, Wuhu, China.
Papers in Europe PMC - 05Zhang Y4 papers · 2025
Department of Oncology Center, Peking University International Hospital, Beijing, People's Republic of China.
Papers in Europe PMC - 06Chen X3 papers · 2026
Department of Pharmacy, West China Hospital of Sichuan University, Chengdu, Sichuan, People's Republic of China.
Papers in Europe PMC - 07Li L3 papers · 2026
Bone Marrow Transplantation Center, The First Affiliated Hospital, Zhejiang University School of Medicine, 79# Qingchun Road, Hangzhou, 310003, China.
Papers in Europe PMC - 08Li S3 papers · 2026
Department of Liver Surgery, State Key Laboratory of Complex Severe and Rare Diseases, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, China.
Papers in Europe PMC - 09Li Y3 papers · 2026
Department of Oncology and Vascular Interventional Therapy, Clinical Oncology School of Fujian Medical University, Fujian Cancer Hospital, Fuzhou, 350014, China.
Papers in Europe PMC - 10Liu Q3 papers · 2026
Department of Oncology, Tangdu Hospital, Fourth Military Medical University, Xi'an, 710038, People's Republic of China.
Papers in Europe PMC
Clinical research
Is a treatment being tested?
0
interventional trials for this specific condition
No interventional trial testing a treatment matched this specific condition name on ClinicalTrials.gov (observational studies and pan-disease registries are listed separately when present).
Data as of 11 September 2026 · last trial check 11 September 2026
No matched interventional trials. This is true for 77.2% of diseases in the trials denominator (5501 of 7126). Here are the researchers publishing on it.
low confidence · 38.6th percentile (trials denominator)
Recruiting interventional trials
From the matched ClinicalTrials.gov set
No interventional trial testing a treatment was found for this specific condition name on ClinicalTrials.gov.
See who's working on it — people publishing on this disease are often the practical next contact when no trial is listed.
Other registries (secondary)
Broader net from EU CTIS, ISRCTN, and ICTRP when available — deduped against ClinicalTrials.gov IDs already counted above. Dual-model LLM relevance gates what we keep. These rows are not added to the interventional headline.
raw 70 · after dedupe 70 · already on CT.gov 0 · kept 0 · parent 0 · uncertain 70 · dropped 0 · fetched 2026-07-30
Source notes: ictrp: Error: ICTRP public search unavailable (WHO portal is SPA-only; SOAP needs partnership). Tried: https://apps.who.int/tri
No secondary-registry studies passed dual-model relevance for this condition name (after dedupe).
Uncertain / not reviewed (70)
- ctis·2022-502402-32-00·Cancelled·Cluster randomised trial of low molecular weight heparins - Directly through Epic
skipped — LLM skipped (--skip-llm)
- isrctn·ISRCTN72157798·Recruiting·Developing a vaccine against Bundibugyo ebolavirus
skipped — LLM skipped (--skip-llm)
- isrctn·ISRCTN98606172·Recruiting·Personalising treatment for myeloma patients based on initial response to NHS treatment and their overall fitness level
skipped — LLM skipped (--skip-llm)
- isrctn·ISRCTN70717445·Recruiting·A clinical trial testing vaccines designed to prevent lung cancer in people at risk of recurrent or new lung cancer
skipped — LLM skipped (--skip-llm)
- isrctn·ISRCTN33436648·Recruiting·The study aims to investigate the effect of the level of probiotic K12 content on enhancing children's immunity and reducing the frequency of their occurrence of diseases such as pharyngitis, tonsillitis, and rhinitis
skipped — LLM skipped (--skip-llm)
- isrctn·ISRCTN14753723·Recruiting·A study to test the safety, tolerability and effect of ZI-MA4-1 for patients with locally advanced or metastatic solid malignancies
skipped — LLM skipped (--skip-llm)
- isrctn·ISRCTN14636207·Recruiting·Sonodynamic therapy using focused ultrasound in glioblastomas
skipped — LLM skipped (--skip-llm)
- isrctn·ISRCTN16472226·Recruiting·Study to test the safety and effectiveness of sutacimig for people with a rare bleeding condition called congenital factor VII deficiency
skipped — LLM skipped (--skip-llm)
- isrctn·ISRCTN41823570·Recruiting·A trial to assess if aspirin with omega-3 and colchicine are medicines that can help recovery from a COPD exacerbation.
skipped — LLM skipped (--skip-llm)
- isrctn·ISRCTN14695157·Recruiting·A study to test the safety of INCB160058 in participants with blood cancers
skipped — LLM skipped (--skip-llm)
- isrctn·ISRCTN52835444·Not yet recruiting·Using eye blood vessel scans to help predict high blood pressure and poor baby growth in pregnancy
skipped — LLM skipped (--skip-llm)
- isrctn·ISRCTN11016599·No longer recruiting·Study of the effect of bridge symptom intervention in symptom management of colorectal cancer patients undergoing postoperative chemotherapy
skipped — LLM skipped (--skip-llm)
- isrctn·ISRCTN13575129·Recruiting·Study to test the non-inferiority of the inactivated trivalent influenza vaccine adjuvanted with IB160 from Instituto Butantan compared to a high-dose inactivated trivalent influenza vaccine in adults aged 60 years and older
skipped — LLM skipped (--skip-llm)
- isrctn·ISRCTN90362708·Recruiting·Bleximenib absorption, metabolism, and excretion in participants with acute leukemia
skipped — LLM skipped (--skip-llm)
- isrctn·ISRCTN82171427·Recruiting·Testing gabapentin to treat distorted senses of smell after a viral infection
skipped — LLM skipped (--skip-llm)
- isrctn·ISRCTN90309905·Recruiting·ViTaL02: A study of a new vaccine against Lassa
skipped — LLM skipped (--skip-llm)
- isrctn·ISRCTN17864800·Recruiting·A new treatment for advanced retinoblastoma in Africa
skipped — LLM skipped (--skip-llm)
- isrctn·ISRCTN62461807·No longer recruiting·A study of a vaccine against Nipah Virus in adults aged 18 to 55 years in Bangladesh
skipped — LLM skipped (--skip-llm)
- isrctn·ISRCTN84894190·No longer recruiting·Immune imbalance in pediatric persistent immune thrombocytopenia
skipped — LLM skipped (--skip-llm)
- isrctn·ISRCTN12573451·Recruiting·Comparing two ways to remove blood clots from the lungs: how different catheter sizes affect heart recovery and patient outcomes in serious pulmonary embolism
skipped — LLM skipped (--skip-llm)
- isrctn·ISRCTN73363779·No longer recruiting·Effect of pulmonary rehabilitation on clinical outcomes in patients with lung cancer
skipped — LLM skipped (--skip-llm)
- isrctn·ISRCTN68248063·Recruiting·Trial of mycophenolate for persistent symptoms of hypothyroidism
skipped — LLM skipped (--skip-llm)
- isrctn·ISRCTN20573724·Recruiting·A study to assess the safety and efficacy of an experimental malaria vaccine by infecting vaccinated and unvaccinated volunteers with malaria parasites
skipped — LLM skipped (--skip-llm)
- isrctn·ISRCTN16084957·No longer recruiting·VITAL01: A study of a new vaccine against Lassa fever in adults aged 18-55 years
skipped — LLM skipped (--skip-llm)
- isrctn·ISRCTN15110009·No longer recruiting·Using genetic testing to personalize heart treatment for patients undergoing stent procedures in Qatar
skipped — LLM skipped (--skip-llm)
Where to find support
Condition-specific patient organisations, when Orphanet lists them, are on the disease’s Orphanet page. We also link umbrella groups that support undiagnosed and ultra-rare families.
Orphanet entry for Hereditary thrombocytopenia with early-onset myelofibrosis — check Associations / patient organisations on that page.
India — NPRD
Last verified 2026-07-26This ORPHAcode is not on our curated NPRD list (direct or Mondo-parent match). That does not decide clinical eligibility; families in India should ask a notified Centre of Excellence about current coverage.
Hand-curated for this project. ORPHAcode mappings are best-effort and may be incomplete or imprecise for umbrella categories. Parent (Mondo) matches mean the policy lists a broader category — confirm eligibility with a Centre of Excellence. Financial entitlements summarised from public policy statements and may change. This is not official government guidance.
How we counted this
Europe PMC query (preferred label + any corrected label + Orphanet and Mondo exact synonyms, stoplisted; unioned with resolved MeSH labels when available). UMLS / OMIM / NCIT cross-references are stored on the overview but are not added to the query string.
("Hereditary thrombocytopenia with early-onset myelofibrosis" OR "thrombocytopenia 6" OR "thrombocytopenia type 6") OR ("SRC syndrome" OR "SRC-related")ClinicalTrials.gov query (quoted phrases + MeSH via query.cond, plus recall-expansion terms when used):
"Hereditary thrombocytopenia with early-onset myelofibrosis" OR "thrombocytopenia 6" OR "thrombocytopenia type 6"
Study-type breakdown: 0 interventional · 0 observational · 0 expanded access. Only interventional studies enter the trial headline.
Query health: ok — strategies attempted: phrase; with hits: phrase
Run this search on ClinicalTrials.gov
Confidence reasoning
- Preferred label is multi-word and distinctive
- No synonyms dropped by stoplist
- No label/synonym collisions with other diseases in this corpus
- Publication count (3369) is implausibly high for prevalence class "<1 / 1 000 000" — treat as possible over-matching, not a measure of research intensity
Ingested 2026-07-27T17:15:01.423Z
